ATE178213T1 - Zur beeinflussung des retikuloendothelialen systems geeignetes arzneimittel - Google Patents

Zur beeinflussung des retikuloendothelialen systems geeignetes arzneimittel

Info

Publication number
ATE178213T1
ATE178213T1 AT92112643T AT92112643T ATE178213T1 AT E178213 T1 ATE178213 T1 AT E178213T1 AT 92112643 T AT92112643 T AT 92112643T AT 92112643 T AT92112643 T AT 92112643T AT E178213 T1 ATE178213 T1 AT E178213T1
Authority
AT
Austria
Prior art keywords
acid
acidic
neutral
pharmaceutically acceptable
water
Prior art date
Application number
AT92112643T
Other languages
English (en)
Inventor
Jozsef Dr Beres
Jun Juzsef Dr Beres
Original Assignee
Beres Export Import Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beres Export Import Rt filed Critical Beres Export Import Rt
Application granted granted Critical
Publication of ATE178213T1 publication Critical patent/ATE178213T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Circuits Of Receivers In General (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
AT92112643T 1991-07-24 1992-07-24 Zur beeinflussung des retikuloendothelialen systems geeignetes arzneimittel ATE178213T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU912492A HU207799B (en) 1991-07-24 1991-07-24 Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis

Publications (1)

Publication Number Publication Date
ATE178213T1 true ATE178213T1 (de) 1999-04-15

Family

ID=10959658

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92112643T ATE178213T1 (de) 1991-07-24 1992-07-24 Zur beeinflussung des retikuloendothelialen systems geeignetes arzneimittel

Country Status (18)

Country Link
US (2) US5312629A (de)
EP (1) EP0524633B1 (de)
JP (1) JP2673852B2 (de)
KR (1) KR100234855B1 (de)
AT (1) ATE178213T1 (de)
BG (1) BG61250B1 (de)
CA (1) CA2074639C (de)
CZ (1) CZ281672B6 (de)
DE (1) DE69228777T2 (de)
FI (1) FI923364A7 (de)
HR (1) HRP920192B1 (de)
HU (1) HU207799B (de)
PL (1) PL169684B1 (de)
RO (1) RO109505B1 (de)
RU (1) RU2093160C1 (de)
SI (1) SI9200155A (de)
SK (1) SK278944B6 (de)
YU (1) YU48243B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
GB9416768D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
US5863519A (en) * 1994-08-18 1999-01-26 Nycomed Imaging As Composition and method of MRI using both a positive and a negative contrast agent
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
RU2146146C1 (ru) * 1999-05-05 2000-03-10 Дубинина Лариса Васильевна Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
US20030170318A1 (en) * 2000-09-29 2003-09-11 Steiner Gregory Gene Fluoride compositions and uses thereof
US6638431B2 (en) * 2001-05-03 2003-10-28 Mainstream Engineering Corporation Formulation and method for treating wetted surface elements in climate control systems
KR20050018250A (ko) * 2003-08-14 2005-02-23 한영주 복합생약 조성물을 함유하는 항암활성을 갖는 조성물
KR100889994B1 (ko) * 2003-08-14 2009-03-24 한영미 녹반을 함유하는 항암활성을 갖는 조성물
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
CN101232821B (zh) * 2005-06-02 2013-01-23 美国硼砂公司 动物和人的骨软骨病的预防和治疗
NZ578133A (en) * 2006-12-06 2012-08-31 Tera Corp B Animal feed compositions comprising supplemental boron and supplemental vitamin c
EP1949894B1 (de) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Verstärkung von vanadiumhaltigen Phosphatasehemmern mit Polyole
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
US10634385B2 (en) 2009-09-03 2020-04-28 Ademco Inc. Heat balancing system
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
AU2014275610B2 (en) 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
WO2015126265A1 (en) * 2014-02-18 2015-08-27 Santos Joyce Bedelia B Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency
ES2908096T3 (es) 2014-04-11 2022-04-27 Gemvax & Kael Co Ltd Péptido con actividad inhibidora de la fibrosis y composición que lo contiene
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
ES2949697T3 (es) 2016-04-07 2023-10-02 Gemvax & Kael Co Ltd Péptido que tiene efectos de aumento de la actividad telomerasa y de extensión de los telómeros, y composición que contienen el mismo
CN114177196B (zh) * 2020-09-14 2025-12-05 深圳市方升泰医药科技有限公司 钒化合物用于治疗疼痛的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022998B (en) * 1978-06-14 1982-09-08 Beres J Phermaceutical composition for the treatment of neoplasticand other diseases
JPS554348A (en) * 1978-06-26 1980-01-12 Peresu Yozefu Drug composition for treating variety of illness by influence to reticuloendotherial tissue and method of treating maligmant tumor with said composition in treating human

Also Published As

Publication number Publication date
RO109505B1 (ro) 1995-03-30
US5312629A (en) 1994-05-17
FI923364A7 (fi) 1993-01-25
KR100234855B1 (ko) 1999-12-15
HRP920192A2 (hr) 1994-04-30
SI9200155A (en) 1993-03-31
PL295352A1 (en) 1993-02-22
DE69228777T2 (de) 1999-10-21
HU912492D0 (en) 1991-12-30
US5405620A (en) 1995-04-11
JPH06227992A (ja) 1994-08-16
CA2074639C (en) 1996-01-09
YU48243B (sh) 1997-08-22
FI923364A0 (fi) 1992-07-24
PL169684B1 (pl) 1996-08-30
CA2074639A1 (en) 1993-01-25
HU207799B (en) 1993-06-28
KR930001915A (ko) 1993-02-22
BG61250B1 (bg) 1997-04-30
EP0524633B1 (de) 1999-03-31
SK278944B6 (sk) 1998-05-06
CZ281672B6 (cs) 1996-12-11
CZ232692A3 (en) 1993-02-17
YU81092A (sr) 1996-01-09
JP2673852B2 (ja) 1997-11-05
BG96686A (bg) 1993-12-24
EP0524633A2 (de) 1993-01-27
DE69228777D1 (de) 1999-05-06
RU2093160C1 (ru) 1997-10-20
EP0524633A3 (en) 1993-07-28
HUT61475A (en) 1993-01-28
HRP920192B1 (en) 2000-06-30
SK232692A3 (en) 1995-06-07

Similar Documents

Publication Publication Date Title
DE69228777D1 (de) Zur Beeinflussung des retikuloendothelialen Systems geeignetes Arzneimittel
AU4950096A (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
GR3021361T3 (en) Orally-ingestible nutrition compositions having improved palatability
AU2054097A (en) Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
GR3030342T3 (en) Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase.
AU5162796A (en) Novel peptide derivatives
BR9610386A (pt) Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica
DE69323229D1 (de) Verfahren zur Bekämpfung von Bakterien-/Pilzkrankheiten in Pflanzen
AU5916998A (en) Non-irritating composition for treating acne and other skin conditions
HUT75119A (en) Crystalline anhydrous mycophenolate mofetil, intravenous pharmaceutical formulation thereof and process for their preparation
GR1002573B (el) Μικροβιακη μεθοδος παρασκευης μεβινολινης.
TNSN95077A1 (fr) Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
CA2116829A1 (en) Use of a pregnane derivative
AU5630794A (en) Highly concentrated TCF pharmaceutical preparations
FR2669221B1 (fr) Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique.
GB2294637A (en) Therapeutic compositions and methods of use
AU2135688A (en) Pharmaceutical composition for preventing and treating bacterial or viral diseases
MY101747A (en) Dihydroorotic acids derivative, processes for preparing the same
AU5214900A (en) Pressed products of non-caking salt
HU9502821D0 (en) Process for the manufacture of aminomethanephosphonic acid
AU2415699A (en) 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
AU660916B2 (en) Beta-hydroxamate D-aspartic acid for treatment of viral infections and tumours
AU2490688A (en) Pharmaceutical product containing vincristine and peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee